

Tirzepatide for Alcohol Use Disorder

NCT06994338

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Southern California
Enrollment	42 participants

Key Eligibility Criteria

Inclusion (8)

- Meeting past-year DSM-5 criteria for AUD with at least moderate severity (e 4 symptoms)
 - Average daily consumption of e40g (women) / e 60 g (men) per day in the 28 days prior to baseline
 - Body mass index e 27kg/m²
 - Willingness to attend weekly medication visits and complete all study procedures
 - Ability to read and communicate in English
- ... and 3 more (see full listing online)

Exclusion (27)

- Meeting past-year DSM-5 criteria for another substance use disorder (except tobacco use disorder or mild cannabis use disorder)
 - Recent (past 30 day) self-report of illicit drug use (excluding cannabis) or non-prescribed opioids; or positive urine screen for illicit drugs. A positive screen for opioids will be allowed if the participant is prescribed an opioid replacement therapy medication and can provide documentation.
 - History of significant alcohol withdrawal, as indicated by history of seizure, delirium tremens; history of hospitalization for withdrawal-related symptoms; a CIWA score \>9 at assessment; or a baseline score 4+ on the Prediction of Alcohol Withdrawal Severity (PAWS) scale.
 - Recent (past 3 months) engagement in behavioral or pharmacological alcohol use treatment or currently mandated to receive treatment
 - History of chronic or acute pancreatitis
- ... and 22 more (see full listing online)

Locations (1 total)

Keck School of Medicine, University of Southern California, Los Angeles, California, United States

<https://clinicaltrials.gov/study/NCT06994338>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.